Artificial Intelligence for healthcare is here to stay. Machine learning and AI have made it possible to search and develop new pharmaceuticals, faster, cheaper, and more effectively. [1]
If you have a biology startup, it may seem obvious to leverage the power of AI to speed up your research – but just because you can, doesn’t mean you should. On October 1, two AI companies partnering with biology startups will present their views on:
· How to build AI into your biotech company and how to start
· How to determine the right timing for integrating AI as a tool
· How to create effective partnerships with big and small to vertically integrate
· How AI companies doing in silico research can employ biology to quickly and efficiently validate research
Following the presentations, Emma Huang, Director of Data Sciences External Innovation, Johnson & Johnson Innovation, will join the companies for a panel discussion on what big pharma has seen, what they’re looking for, and how startups can differentiate themselves.
Source: [1]https://www.nature.com/articles/d41586-018-05267-x
Bevan Emma Huang, Ph.D., is the Director of Data Sciences External Innovation at the California Innovation Center, where she sources, evaluates, and facilitates external partnering opportunities in data sciences across all sectors of Johnson & Johnson. She is an experienced data scientist with years of research leadership in integrating diverse data modalities to generate efficiencies and novel insights.
As Head of Johnson & Johnson Innovation, JLABS in Canada, Allan is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. He catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, consumer and healthtech sectors.
Naheed Kurji is the President and CEO of Cyclica, a Toronto-based biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica provides the pharmaceutical industry with an integrated, holistic, and end-to-end enabling platform that enhances how scientists design, screen, and personalize medicines for patients.
Prior to co-founding twoXAR, Andrew held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew developed the company's proprietary algorithm and as Chief Executive Officer is focused on overall company strategy, product development and fundraising. Andrew studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.
Johnson & Johnson Innovation – JLABS Notice
The views expressed during this event, including during any associated networking and/or individual meetings by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such experts or speakers are solely responsible for the information and opinions expressed by them. By hosting this event, the presentations and any associated networking and/or individual meetings, JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information
